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Abstract
Background
Autoimmune conditions (AICs) and/or their treatment may alter risk of human papilloma
virus (HPV) infection and females with AICs are therefore at an increased risk of cervical
dysplasia. However, inclusion of these at-risk populations in cervical cancer screening and
HPV-vaccination guidelines, are mostly lacking. This study aimed to determine the preva-
lence of cervical dysplasia in a wide range of AICs and compare that to HIV and immuno-
competent controls to support the optimisation of cervical cancer preventive health
measures.
Methods
Data linkage was used to match cervical screening episodes to emergency department rec-
ords of females with AICs or HIV to immunocompetent controls over a 14-year period. The
primary outcome was histologically confirmed high-grade cervical disease. Results, mea-
sured as rates by cytology and histology classification per 1,000 females screened, were
analysed per disease group, and intergroup comparisons were performed.
Results
Females with inflammatory bowel disease (2,683), psoriatic and enteropathic arthropathies
(1,848), multiple sclerosis (MS) (1,426), rheumatoid arthritis (1,246), systemic lupus
PLOS ONE
PLOS ONE | https://doi.org/10.1371/journal.pone.0234813 June 18, 2020 1 / 14
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Foster E, Malloy MJ, Jokubaitis VG,
Wrede CDH, Butzkueven H, Sasadeusz J, et al.
(2020) Increased risk of cervical dysplasia in
females with autoimmune conditions—Results
from an Australia database linkage study. PLoS
ONE 15(6): e0234813. https://doi.org/10.1371/
journal.pone.0234813
Editor: Magdalena Grce, Rudjer Boskovic Institute,
CROATIA
Received: February 9, 2020
Accepted: June 2, 2020
Published: June 18, 2020
Copyright: © 2020 Foster et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: Data cannot be
shared publicly because of the potentially re-
identifiable nature of the data due to location of
participants, age, and location of practice (i.e state
and postcode) and individual qualitative responses
recorded in the survey database. Data are available
from the Victorian Cytoloy Service after approval
obtained from the Victorian Department of Health
and Human Services Human Research Ethics
Committee (study number 01/11) for researchers
who meet the criteria for access to confidential
erythematosus and/or mixed connective tissue disease (SLE/MCTD) (702), HIV (44), and
985,383 immunocompetent controls were included. SLE/MCTD and HIV groups had greater
rates of high-grade histological and cytological abnormalities compared to controls.
Increased rates of low-grade cytological abnormalities were detected in all females with
AICs, with the exception of the MS group.
Conclusions
Females with SLE/MCTD or HIV have increased rates of high-grade cervical abnormalities.
The increased low-grade dysplasia rate seen in most females with AICs is consistent with
increased HPV infection. These findings support expansion of cervical cancer preventative
programs to include these at-risk females.
Introduction
Human papillomavirus (HPV) is the most common sexually transmitted infection, and high-
risk types such as HPV 16 and 18 are oncogenic and associated with pre-malignant and malig-
nant conditions of the cervix and anogenital lesions [1]. Control of HPV infection relies upon
an effective local immune response and therefore diseases associated with impaired immunity,
either due to the disease itself or immunomodulatory treatment, can increase the risk of HPV-
related conditions [2]. Heavily immunocompromised females, such as those with untreated
human immunodeficiency virus (HIV), are most at risk of cervical, vaginal or vulval intra-epi-
thelial dysplasia and HPV-related cancers [3,4]. Population-wide cohort studies have shown
an increased risk of cervical abnormalities in females with autoimmune conditions including
inflammatory bowel disease (IBD) [5], systematic lupus erythematosus (SLE) [6], and rheuma-
toid arthritis (RA) [7], especially if treated with immunomodulatory therapy. There is limited
data regarding the risk of persistent HPV infection, cervical dysplasia and HPV-related cancers
in females with multiple sclerosis (MS) [8].
Despite the existing evidence, cervical cancer prevention guidelines typically lack a compre-
hensive approach to these at-risk individuals even though many countries do recommend
more frequent cervical screening in immunocompromised individuals [9]. Prophylactic HPV
vaccination is a complementary public health measure to cervical screening. However, the
optimal use of the vaccine in immunocompromised populations is not well defined [9].
National guidelines in many countries recommend a two-dose schedule for immunocompe-
tent females aged 11–14 years, as the vaccine is most immunogenic at a younger age and con-
fers the greatest benefit when given prior to HPV exposure (i.e. before first sexual activity)
[10]. Three doses are recommended in those immunocompromised at time of vaccination
(regardless of age) and for those aged 15 years or older at first dose.
Australia is a world leader in cervical cancer prevention and is predicted to be one of the
first countries to achieve elimination of cervical cancer as a public health problem [11]. How-
ever, the lack of local data on the burden of disease amongst immunocompromised females
has arguably resulted in delays optimising public health policy. Autoimmune conditions have
a preponderance in young to middle aged females and many would not have had the opportu-
nity to receive the HPV vaccine as teenagers. In addition, the financial barrier posed by recom-
mending HPV vaccination outside of the targeted age range is substantial, and, data
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supporting the potential benefits of an expanded indication for prophylactic vaccination in
this group are required.
Here, we report and compare rates of cervical abnormalities in females with a wide range of
autoimmune conditions in Australia. We included SLE/mixed connective tissue disease
(MCTD), RA, psoriatic and enteropathic arthropathies (PsA and EA), IBD, MS and primary
immunodeficiencies or HIV and comparison with an immunocompetent community cohort.
Methods
We undertook a retrospective cohort study utilising data collected from 1 January 2000 to 31
December 2013 in the state of Victoria, Australia. In 2006, the mid-point of the study period,
Victoria’s population was 5.13 million with 50.5% female [12]. Inclusion criteria were females
aged 15 and over who attended any public Victorian hospital emergency department, as iden-
tified through the Victorian Emergency Minimum Dataset (VEMD) and had ever undergone
community cervical screening in the study period, as identified through deterministic data
linkage to the Victorian Cervical Cytology Registry (VCCR). The VCCR recorded cervical
screening cytology and histopathology results for Victorian females, with < 1% opting off the
registry [13]. Females identified during the study period to have an autoimmune condition,
primary immunodeficiency or HIV as per VEMD discharge diagnoses (S1 Appendix) were
assigned to that study group (S2 Appendix) for the duration of the study period. These study
groups were compared to presumed immunocompetent controls (i.e. those females who did
not have any episodes with these conditions identified via the VEMD). We excluded females
recorded as having cervical cancer, hysterectomy or as deceased prior to entry into the study.
Deterministic matching was performed by the Centre for Victorian Data Linkage (CVDL)
to identify females common to both VCCR and VEMD. Analytic variables used for matching
were name, address, postcode, Medicare number, sex and date of birth. VCCR variables
returned to investigators for analysis were age (month/year of birth), cervical screening history
at the episode level and postcode (used to assign remoteness area and area level socioeconomic
status). VEMD variables were age (month/year of birth), Aboriginal and Torres Strait Islander
status, country of birth, reason for attendance (coded according to ICD10-AM) and atten-
dance date (as month/year), and statistical local area.
Histological and cytological outcomes were assigned according to Australian Institute of
Health and Welfare (AIHW) categorisation and Australian Standardised Modified Bethesda
System, respectively [14]. The primary outcome was histologically confirmed high-grade cervi-
cal disease defined as cervical intra-epithelial neoplasia (CIN2, CIN3, adenocarcinoma in situ
(AIS) or mixed CIN3/AIS). A female that had multiple outcomes in the study period, e.g. both
a cytological low-grade, and a histological high-grade abnormality, was counted for each out-
come independently in separate analyses run for each outcome. Females needed to have two
negative tests over two years in order for a second abnormality to be recorded as an incident
abnormality; two negative Pap tests was assumed to equate to a confirmed clearance period.
Person-time was counted until the outcome of interest, date of death, hysterectomy, 2.5 years
post their last negative cytology test, or the end of the study period, whichever came first.
Ethics approval and consent
This study was approved by the Victorian Department of Health and Human Services Human
Research Ethics Committee (study number 01/11). All data were fully anonymized before
researchers accessed them, and ethics committee waived the requirement for informed
consent.
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Statistical methods
The Mann-Whitney U test was applied to compare the means of the continuous variables and
Pearson chi-squared test for nominal variables. Where a comparison contained expected
frequencies < 10, Fisher’s exact test was applied. Normality of continuous variables was
assessed using the Shapiro-Wilk test. Cox regression, with age as the time axis, was used to esti-
mate hazard ratios (HR) with 95% confidence intervals (CI) of cervical abnormalities accord-
ing to study group status. Using an entry-age-adjusted age-scale as the time axis allows the
baseline hazard to change as a function of age, better controlling for potential confounding
due to age [15]. Covariates analysed included number of screening episodes, area level socio-
economic status assigned from postcode in quintiles using the Australian Bureau of Statistics
Socio-Economic Indexes for Areas Index of Relative Socio-Economic Disadvantage [16],
remoteness area assigned from postcode using the Australian Standard Geographic Classifica-
tion for 2011 [17], Aboriginal and/or Torres Strait Islander status, and country of birth in
Major Categories (Appendix 3) [18]. Any covariates that violated the Cox model assumption
of proportional hazards were stratified out of each model. Kaplan-Meier curves were derived
using time-on-study, i.e. follow-up time, as the time axis. Incidence rates by cytology and his-
tology classification were calculated per disease group and on the scale of per 1,000 person-
years. Intergroup comparisons were then performed.
Results
We identified 985,383 females in the control cohort, 7,905 in the autoimmune condition
cohort, 44 in the HIV cohort and none in the primary immunodeficiency cohort over the
14-year study period (Fig 1). The overall median follow-up time from study entry to end-point
was 9.43 years. Of the females with an autoimmune condition, 2,683 (33.9%) were diagnosed
with IBD, 1,848 (23.4%) PsA and EA, 1,426 (18.0%) with MS, 1,246 (15.8%) with RA and 702
(8.9%) with SLE/MCTD.
Compared to controls, females in the autoimmune condition cohort had higher mean age
at study entry (35.5 years vs 34.8 years, p<0.001), were less likely to live in major cities (71.3%
vs 75.7%, p<0.001), were more likely to be in the lowest socioeconomic bracket (21.9% vs
18.3%, p<0.0001) and to identify as Aboriginal or Torres Strait Islander (1.5% vs 1.1%,
p = 0.001). (Table 1) On average, the mean number of Pap tests performed was significantly
higher for females in the autoimmune cohort (n = 4.48, p<0.001) and HIV cohort (n = 5.64,
p<0.035) compared to controls (n = 4.35). Females in the autoimmune condition cohort with
abnormalities detected had a significantly higher mean number of Pap tests compared to con-
trols with abnormalities (n = 6.57 vs n = 6.35, p = 0.003).
Outcome data and main results
SLE/MCTD and HIV groups had significantly higher rates of high-grade histological and
cytological abnormalities than controls. These groups, along with IBD, PsA, EA and RA
groups, also had significantly higher rates of low-grade cytological abnormalities than con-
trols (Table 2). Figs 2 and 3 display cumulative incidence of low- and high-grade cytological
abnormalities and of high-grade histological abnormalities for conditions of interest com-
pared to controls.
HIV
Females with HIV had significantly higher rates of high-grade histological abnormalities
(19.40 vs 3.76 per 1,000 person-years, AHR = 4.89, p<0.001), high-grade cytological
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abnormalities (23.84 vs 6.26 per 1,000 person-years, AHR = 3.43, p = 0.001) and low-grade
cytological abnormalities (48.46 vs 19.99 per 1,000 person-years, AHR = 2.23, p = 0.003).
SLE/MCTD
Females with SLE/MCTD had significantly higher rates of high-grade histological abnormali-
ties (5.57 vs 3.76 per 1,000 person-years, AHR = 1.47, p = 0.033), significantly higher rates of
Fig 1. Flowchart of data linkage process and exclusions for analysis.
https://doi.org/10.1371/journal.pone.0234813.g001
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Table 1. Descriptive characteristics of the control, auto-immune condition (AIC) and HIV cohorts.
Control AIC P-value^ HIV P-value#
Number of individuals a 985,383 7,905 44
Mean age at entry to study in Years (SD) 34.79 (±13.16) 35.52 (±13.09) <0.001 33.64 (±11.02) 0.840
Mean number of Pap tests (SD) 4.35 (±2.79) 4.48 (±2.87) <0.001 5.64 (±4.01) 0.035
Mean number of Pap tests by abnormality status (SD)
No abnormalities 3.75 (±2.35) 3.76 (±2.33) 0.696 4.05 (±2.24) 0.460
One or more abnormalities 6.35 (±3.20) 6.57 (±3.23) 0.003 7.23 (±4.75) 0.647
Age at entry to study (Years)
<30 421,587 (42.78%) 3,132 (39.62%) <0.001 18 (40.91%) 0.802
30–39 240,747 (24.43%) 2,053 (25.97%) 0.002 12 (27.27%) 0.661
40–49 161,484 (16.39%) 1,397 (17.67%) 0.002 9 (20.45%) 0.420�
50–59 106,424 (10.80%) 845 (10.69%) 0.752 5 (11.36%) 0.809�
> = 60 55,141 (5.60%) 478 (6.05%) 0.082 0 (0%) 0.177�
Remoteness area b
Major cities 743,978 (75.67%) 5,619 (71.26%) <0.001 32 (74.42%) 0.848
Inner regional 197,510 (20.09%) 1,886 (23.92%) <0.001 8 (18.60%) 1.000�
Outer regional 41,376 (4.21%) 376 (4.77%) 0.014 3 (6.98%) 0.428
Remote/Very Remote 317 (0.03%) 4 (0.05%) 0.331� 0 (0%) 1.000�
Socioeconomic status c
1 (Lowest) 179,394 (18.30%) 1,725 (21.92%) <0.001 10 (23.26%) 0.428�
2 138,478 (14.12%) 1,251 (15.90%) <0.001 4 (9.30%) 0.510�
3 170,748 (17.42%) 1,442 (18.33%) 0.034 8 (18.60%) 0.840�
4 227,866 (23.24%) 1,822 (23.16%) 0.859 7 (16.28%) 0.280
5 (Highest) 263,910 (26.92%) 1,628 (20.69%) <0.001 14 (32.56%) 0.404
Cytological abnormalities diagnosed on entry into cohort d
Cancer 80 (0.01%) 1 (0.01%) 0.477� 0 (0%) 1.000�
High-grade
Definite 8,459 (0.86%) 75 (0.95%) 0.389 4 (9.09%) 0.001�
Possible 5,913 (0.60%) 45 (0.57%) 0.721 1 (2.27%) 0.233�
Glandular 85 (0.01%) 1 (0.01%) 0.497� 0 (0%) 1.000�
Low-grade 54,065 (5.49%) 488 (6.17%) 0.008 6 (13.64%) 0.032�
Negative 897,539 (91.14%) 7,151 (90.46%) 0.034 32 (72.73%) <0.001�
Unsatisfactory 18,646 (1.89%) 144 (1.82%) 0.641 1 (2.27%) 0.569�
Aboriginal & Torres Strait Islander Status e
Aboriginal Only 6,484 (0.66%) 95 (1.20%) <0.001 0 (0%) 1.000�
Torres Strait Islander Only 402 (0.04%) 3 (0.04%) 1.000� 0 (0%) 1.000�
Aboriginal & Torres Strait Islander 1,751 (0.18%) 15 (0.19%) 0.800 1 (2.27%) 0.075�
Neither Aboriginal or Torres Strait Islander 974,541 (98.90%) 7,788 (98.52%) 0.001 43 (97.73%) 0.385�
Question unable to be asked 1,843 (0.19%) 4 (0.05%) 0.005 0 (0%) 1.000�
Patient refused to answer 362 (0.04%) 0 (0%) 0.127� 0 (0%) 1.000�
Country of Birth (Major Categories) f
Americas 12,724 (1.29%) 89 (1.13%) 0.194 0 (0%) 1.000�
North Africa & The Middle East 22,826 (2.32%) 206 (2.61%) 0.088 1 (2.27%) 1.000�
North-East Asia 19,859 (2.02%) 56 (0.71%) <0.001 1 (2.27%) 0.592�
North-West Europe 54,222 (5.50%) 457 (5.78%) 0.280 1 (2.27%) 0.517�
Oceania & Antarctica 730,329 (74.12%) 6,186 (78.25%) <0.001 32 (72.73%) 0.833
South-East Asia 32,519 (3.30%) 141 (1.78%) <0.001 4 (9.09%) 0.057�
Southern & Central Asia 27,079 (2.75%) 125 (1.58%) <0.001 1 (2.27%) 1.000�
(Continued)
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high-grade cytological abnormalities (8.25 vs 6.26 per 1,000 person-years, AHR = 1.33,
p = 0.051), and significantly higher rates of low-grade cytological abnormalities (26.03 vs 19.99
per 1,000 person-years, AHR = 1.36, p<0.001).
IBD
Females with IBD had significantly higher rates of low-grade cytological abnormalities com-
pared to controls (25.30 vs 19.99 per 1,000-person years, AHR = 1.19, p<0.001).
Psoriatic and enteropathic arthropathies. Females with PsA or EA had significantly
higher rates of low-grade cytological abnormalities compared to controls (23.73 vs 19.99,
AHR = 1.12, p = 0.035).
RA
Females with RA had significantly higher AHR of low-grade cytological abnormalities com-
pared to controls (17.14 vs 19.99 per 1,000 person-years, AHR = 1.23, p = 0.008).
MS
Females with MS had no significant differences in rates of high-grade histological abnormali-
ties (3.07 vs 3.76 per 1,000 person-years, AHR = 0.78, p = 0.124), high-grade cytological abnor-
malities (5.98 vs 6.26 per 1,000 person-years, AHR = 0.98, p = 0.836) or low-grade cytological
abnormalities (20.45 vs 19.99 per 1,000 person-years, AHR = 1.10, p = 0.139) compared to
controls.
Discussion
This study suggests that females with HIV and with SLE/MCTD are at 5 times and 1.5 times
greater risk, respectively, of high-grade cervical abnormalities compared to controls after
adjustment for age-at-entry, socioeconomic status and screening frequency. These conditions,
along with IBD, PsA, EA and RA, were also associated with greater rates of low-grade
Table 1. (Continued)
Control AIC P-value^ HIV P-value#
Southern & Eastern Europe 60,659 (6.16%) 524 (6.63%) 0.082 1 (2.27%) 0.523�
Sub-Saharan Africa 12,069 (1.22%) 91 (1.15%) 0.553 3 (6.82%) 0.017�
Not Classified 13,097 (1.33%) 30 (0.38%) <0.001 0 (0%) 1.000�
SD = Standard deviation, AIC = Autoimmune Condition, HIV = Human Immunodeficiency Virus
^ P-value compares cases against controls
# P-value compares HIV cohort against controls
� P-value calculated using Fisher’s Exact Chi-Squared test.
a The total number of individuals is 993,332.
b Individuals were allocated to a remoteness area based on their postcode of usual residence, according to the Australian Standard Geographic Standard (ASGS) for
2011. Missing data on 2,223 individuals (0.22%; 2,202 controls, 20 cases: Crohn’s x 2, MS x 2, Arthropathies x 6, RA x 2, SLE x 1, UC x 7 and 1 HIV) were excluded.
c Individuals were allocated to a socioeconomic status (SES) groups based on their postcode of usual residence, according to the Australian Bureau of Statistics Socio-
Economic Indexes for Areas (SEIFA) Index of Relative Socio-Economic Disadvantage. Missing data on 5,025 individuals (0.51%; 4,987 controls, 37 cases: Crohn’s x 7,
MCTD x 1, MS x 3, Arthropathies x 11, RA x 4, SLE x 2, UC x 9 and 1 HIV) were excluded.
d 596 individuals (0.06%; 596 controls) were excluded as they only had histological episodes.
e Aboriginal & Torres Strait Islander classification was determined by using the ‘Ever Aboriginal & Torres Strait Islander’ method
f Country of Birth classification was determined by using the ‘Majority’ method
https://doi.org/10.1371/journal.pone.0234813.t001
PLOS ONE Cervical dysplasia in autoimmune diseases
PLOS ONE | https://doi.org/10.1371/journal.pone.0234813 June 18, 2020 7 / 14
Table 2. Number, incidence rate and adjusted hazard ratios for cervical abnormalities of the control, auto-immune conditions and HIV cohorts.
Outcome Cohort Number of
Women
Number of
Abnormalities
Person-Years Rate� 95% CI AHR 95% CI P-value
Histological abnormalities
All high-grade
histologya
Control 985,383 30,963 8,241,438.70 3.76 3.72 to 3.80 Reference
AIC 7,905 274 68,046.96 4.03 3.58 to 4.53 1.03 0.91 to 1.16 0.654
HIV 44 7 360.83 19.40 9.25 to 40.69 4.89 2.33 to
10.27
<0.001
IBD 2,683 107 23,250.72 4.60 3.81 to 5.56 1.02 0.85 to 1.24 0.824
SLE, MCTD 702 32 5,746.52 5.57 3.94 to 7.87 1.47 1.03 to 2.09 0.033
MS 1,426 40 13,021.47 3.07 2.25 to 4.19 0.78 0.57 to 1.07 0.124
PsA and EA 1,848 70 15,559.44 4.50 3.56 to 5.69 1.11 0.88 to 1.41 0.367
RA 1,246 25 10,468.81 2.39 1.61 to 3.53 0.96 0.65 to 1.43 0.856
Cytological abnormalities
High-grade cytologya Control 985,383 51,143 8,168,425.90 6.26 6.21 to 6.32 Reference
AIC 7,905 451 67,415.89 6.69 6.10 to 7.34 1.06 0.97 to 1.17 0.196
HIV 44 8 335.59 23.84 11.92 to
47.67
3.43 1.64 to 7.21 0.001
IBD 2,683 177 23,036.70 7.68 6.63 to 8.90 1.12 0.96 to 1.29 0.144
SLE, MCTD 702 47 5,697.80 8.25 6.20 to 10.98 1.33 1.00 to 1.78 0.051
MS 1,426 77 12,882.54 5.98 4.78 to 7.47 0.98 0.78 to 1.22 0.836
P & E Arthropathies 1,848 101 15,404.55 6.56 5.39 to 7.97 0.97 0.80 to 1.18 0.769
Rheumatoid
Arthritis
1,246 49 10,394.30 4.71 3.56 to 6.24 1.03 0.78 to 1.37 0.820
Low-grade cytologyb Control 985,383 155,415 7,773,743.60 19.99 19.89 to
20.09
Reference
AIC 7,905 1,444 63,353.00 22.79 21.65 to
24.00
1.17 1.11 to 1.24 <0.001
HIV 44 15 309.50 48.46 29.22 to
80.39
2.23 1.32 to 3.76 0.003
IBD 2,683 545 21,539.72 25.30 23.26 to
27.52
1.19 1.09 to 1.29 <0.001
SLE, MCTD 702 137 5,263.87 26.03 22.01 to
30.77
1.36 1.15 to 1.61 <0.001
MS 1,426 251 12,276.65 20.45 18.07 to
23.14
1.10 0.97 to 1.24 0.139
P & E Arthropathies 1,848 342 14,412.69 23.73 21.34 to
26.38
1.12 1.01 to 1.25 0.035
Rheumatoid
Arthritis
1,246 169 9,860.06 17.14 14.74 to
19.93
1.23 1.05 to 1.42 0.008
CI = Confidence Interval, AHR = Adjusted Hazard Ratio, AIC = Autoimmune Condition, HIV = Human Immunodeficiency Virus, IBD = Inflammatory Bowel Disease
(Crohn’s Disease & Ulcerative Colitis), SLE = Systemic Lupus Erythematosus, MCTD = Mixed Connective Tissue Disease, MS = Multiple Sclerosis, P & E
Arthropathies = Psoriatic & Enteropathic Arthropathies
� Rate per 1,000 person-years.
a Cox model stratified by remoteness, country of birth and number of screening tests. Other co-variables adjusted for include: socio-economic status and indigenous
status.
b Cox model stratified by socio-economic status, country of birth and number of screening tests. Other co-variables adjusted for include: indigenous status.
All high grade histology defined as CIN2, CIN3, AIS and mixed CIN3/AIS.
High-grade cytology defined as possible high-grade squamous intraepithelial lesion (HSIL), HSIL, HSIL with possible microinvasion/invasion, squamous cell
carcinoma, possible high-grade endocervical glandular lesion and AIS.
Low-grade cytology defined as possible low-grade squamous intraepithelial lesions (LSIL), LSIL and atypical endocervical cells of uncertain significance.
https://doi.org/10.1371/journal.pone.0234813.t002
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cytological abnormalities, indicating higher HPV infection rates. Similar to previously
reported findings [8], we found no significant differences in rates of cervical abnormalities
between females with MS and controls.
The increased incidence of cervical abnormalities in females with these conditions is consis-
tent with a previous meta-analyses that showed an increased risk of cervical dysplasia in SLE
(OR 4.17 (95% CI 3.03, 5.74) [3,6] and IBD (OR 1.34 (95% CI 1.23–1.46) compared to controls
[5]. Similarly, Swedish registry data reported an increased risk low-grade cytological lesions in
RA [7], while cervical dysplasia rates in PsA and EA have not been previously been reported.
Altered immune surveillance due to both intrinsic disease-related factors and/or immuno-
modulatory therapies have been postulated to contribute to this risk. Immunodeficiency and
immune dysregulation frequently coexist in autoimmune disease. As such, patients with auto-
immune conditions such as SLE, RA and psoriasis may present with disturbances in their
immune system, and, conversely, primary immunodeficiencies can first present as autoim-
mune conditions [19]. MS is a possible exception to this given the single-tissue target, i.e. the
central nervous system, of autoimmunity. In addition, the immune-pathogenesis of MS is
increasingly recognized to evolve over the disease course from an initial peripheral, T-cell
driven, immune response to a CNS dominant process later in the disease that is largely driven
by the innate immune system [20].
Immune clearance and control of HPV requires cell mediated immunity and T-cell func-
tioning, hence the observation of higher rates of infection and HPV-related diseases in
Fig 2. Cumulative incidence of cytological high-grade and low-grade abnormalities. Cumulative incidence of
cytological high grade (CHG) and Cytological low grade (CLG) abnormalities compared to healthy controls in a) Crohn’s
disease/Ulcerative colitis. b) HIV c) SLE/MCTD d) MS e) PsA and EA and f) RA. UC = Ulcerative colitis; HIV = Human
immunodeficiency virus; SLE/MCTD = Systemic Lupus Erythematosus/ Mixed Connective Tissue Disease;
MS = multiple sclerosis; P&E = psoriatic arthritis and enteropathic arthropathy; RA = Rheumatoid arthritis.
https://doi.org/10.1371/journal.pone.0234813.g002
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conditions where such immune control is compromised [2]. A wider diversity of HPV types
and multiple types of infections are more frequently detected amongst immunocompromised
females. However, cervical dysplasia and cancer are still predominantly caused by the most
oncogenic types, HPV 16 and 18, although to a lesser extent than amongst immunocompetent
females. The low risk types HPV 6 and 11, still predominate in genital warts [21,22].
Prophylactic HPV vaccination is believed to provide protection against infection through
induction of antibodies, which are present at the sites of minor epithelial trauma and bind to
virus there, preventing the virus from entering the basal epithelial cells [23]. The currently
licensed HPV vaccines do not assist with viral clearance, i.e. they are not therapeutic, but, in
already or previously infected females, they may prevent new infection with other HPV types,
reinfection, and further spread of virus to other areas of the genital tract. This has been sug-
gested based on observations of lower rates of recurrent disease in vaccinated females previ-
ously treated for high grade cervical disease [24]. These principles also apply to the vaccination
of already sexually active females who are immunocompromised, as they may benefit from
vaccination in these ways even if they have already been exposed to HPV [9]. Ideally, HPV vac-
cination should have occurred routinely in early adolescence prior to sexual activity but immu-
nocompromised females have a greater potential capacity to benefit from later vaccination
than the general population. The nonavalent HPV vaccine provides protection against the low
risk types HPV 6 and 11 as well as seven oncogenic HPV types (16,18,31,33,45,52,58) and
Fig 3. Cumulative incidence of histological high-grade abnormalities. Cumulative incidence of histological high
grade abnormalities compared to healthy controls in a) Crohn’s disease/Ulcerative colitis. b) HIV c) SLE/MCTD d) MS
e) Psoriatic and enteropathic arthropathy and f) RA. UC = Ulcerative colitis; HIV = Human immunodeficiency virus;
SLE/MCTD = Systemic Lupus Erythematosus/ Mixed Connective Tissue Disease; MS = multiple sclerosis;
P&E = psoriatic arthritis enteropathic arthropathy; RA = Rheumatoid arthritis.
https://doi.org/10.1371/journal.pone.0234813.g003
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might be considered even in those who have already received either quadrivalent or bivalent
HPV vaccine to extend the number of HPV types protected against. For females who previ-
ously commenced but did not complete HPV vaccination courses prior to onset of immuno-
modulatory therapy, the course can be completed with nonavalent HPV vaccine without
needing to restart the course.
The risk of long term exposure to immunomodulatory therapies may be considerable as
treatment tends to be initiated at a young age and continue for decades, or even lifelong. Exist-
ing studies are limited by sample size, and to date, azathioprine is the only immunosuppressant
commonly used in autoimmune conditions shown to increase the risk of cervical cancer (HR
of 1.4 [95% CI: 0.9–2.1]) [25]. The risk of cervical cancer was twofold in females who received
a high cumulative dose of>300 defined daily doses of azathioprine (HR of 2.2, 95% CI 5 1.2–
3.9). Despite the increasingly specific mode of action of newer immunotherapies, many have
only been available for short periods and data on long-term effects such as HPV infection and/
or cervical cancer are unknown. Moreover, the risk attributable to various therapies is difficult
to separate from factors such as medication dose, duration, concurrent medications and
underlying disease severity. Given that oncogenesis from HPV infection typically develops
over decades, ongoing surveillance and study is warranted [26] and a pro-active approach to
safety is important.
Several strengths of this study should be noted. We examined a large cohort of Australian
females and include a wide spectrum of rare auto-immune diseases and HIV. The inclusion of
an HIV cohort, where the high risk of cervical dysplasia and cancer is well established and
associated with the degree of immunodeficiency, provides a unique context to these results.
This is the first study to report rates of cervical dysplasia or cervical cancer in patients with
psoriatic arthritis or enteropathic arthritis. Age is known to be a major confounder of analys-
ing cervical dysplasia data and we therefore report the rates and risks with an entry-age-
adjusted age-scale. The distribution of normal and abnormal screening results at baseline in
the cohort is similar to that for all Victorian females as reported by registry data (cohort vs reg-
istry: 91.1% vs 91.1% negative, 5.5% vs 4.6% low grade, 1.5 vs1.3% high grade) [13]. Contem-
porary guidelines recommended that immunocompromised patients underwent yearly Pap
tests, which increased the chance of identifying transient infections. Although our analysis
adjusted for frequency of testing, it cannot fully remove this increased ascertainment bias of
cervical abnormalities in our analyses.
Our data did not include duration of disease, presence and duration of immunomodulatory
therapy, HPV vaccination status (which is known to reduce cervical dysplasia risk in young
females in Victoria) [27] or risk factors for cervical cancer such as cigarette smoking, use of
oral contraception, multiparity, body mass index, sexual history, and young age at first full-
term pregnancy [28]. We did control for age, number of tests, socioeconomic status and
remoteness of residence, which provides some control for underlying demographic character-
istics which may be correlated with some of these factors (e.g. smoking). As such, although this
study provides insights as to comparative risks within this cohort, it cannot be used to estimate
risk at the level of the individual. Whilst we identified a higher proportion of Aboriginal
women within the autoimmune than control cohort, caution is warranted in interpretation
given potential limitations of self-identification in emergency department data, the method
used to classify disease status, and limited corroborating evidence of an increased risk of these
diseases in Aboriginal women [29,30]. Variables such as HPV vaccination status, cigarette
smoking, use of oral contraception, multiparity, body mass index, sexual history, and young
age at first full-term pregnancy would be important to consider in future research regarding
risk of cervical dysplasia. Data linkage at a national level, and with clinical databases which
include variables such as type, dose and duration of immunomodulatory therapies, would
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increase power and provide a more accurate model of risk of cervical abnormalities in popula-
tions with these rare autoimmune conditions.
The study design included females who had ever presented to public hospital emergency
departments in Victoria over a period of 14 years. However, as the majority of patients with
autoimmune conditions are well and managed in outpatient settings, there may be an over-
representation of females with more active disease included in the autoimmune cohort. About
20% of Australians with chronic illnesses attend emergency departments every year; this study
therefore would capture many, but not all, females living with autoimmune conditions or HIV
in our community [31]. Further, a primary and two additional diagnoses are recorded per
patient per emergency department attendance. This may lead to under-ascertainment of
females with autoimmune conditions or HIV, as these conditions may not be recorded if not
directly relevant to the hospital episode or if other diagnoses are recorded as a priority.
Conclusions
In summary, most autoimmune conditions appear to increase the risk of cervical HPV infec-
tion and related disease. These data have important public health implications especially in
countries where cervical screening programs are lacking. The expansion of eligibility for
funded vaccination to females with these conditions to optimise cervical cancer prevention
programs should be considered. Further research to better understand risks relating to dura-
tion and type of immune-therapy and other known risk factors are needed in females with
auto-immune conditions.
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